Using contrast agents to improve liver cancer radiation therapy
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
This study is testing if using special contrast agents can help doctors better track liver tumors during radiation therapy for patients who have already received a different treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Sydney Academic / other |
| Drugs / interventions | radiation |
| Locations | 5 sites (Waratah, New South Wales and 4 other locations) |
| Trial ID | NCT05169177 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of radio-opaque contrast agents in tracking liver tumors during stereotactic ablative body radiation therapy (SABR). It involves collecting image files from patients who have received SABR after trans-catheter arterial chemoembolization (TACE). The study aims to develop a software algorithm (KIM) that can accurately detect and track these contrast agents in real-time, enhancing the precision of radiation therapy. Data from 80% of participants will be used to create the algorithm, while the remaining 20% will validate its accuracy against manual delineation of tumor positions.
Who should consider this trial
Good fit: Ideal candidates are adults with liver cancer who are receiving SABR and have been administered a radio-opaque contrast agent visible on imaging scans.
Not a fit: Patients under 18 years old or those without compatible imaging datasets will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of radiation therapy for liver cancer patients, potentially leading to better treatment outcomes.
How similar studies have performed: While the use of imaging software in radiation therapy is established, this specific approach using radio-opaque contrast agents for liver cancer tracking is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site. * Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan * The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking. * Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited) Exclusion Criteria: * Less than 18 years of age * Minimum image dataset is not available * Image dataset is not in a compatible format
Where this trial is running
Waratah, New South Wales and 4 other locations
- Calvary Mater Newcastle Hospital — Waratah, New South Wales, Australia (Not_yet_recruiting)
- Westmead Hospital — Westmead, New South Wales, Australia (Not_yet_recruiting)
- Princess Alexandra Hospital — Woolloongabba, Queensland, Australia (Recruiting)
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (Not_yet_recruiting)
- The Austin Hospital — Melbourne, Victoria, Australia (Not_yet_recruiting)
Study contacts
- Study coordinator: Shona Silvester
- Email: Shona.Silvester@sydney.edu.au
- Phone: +61 2 8627 1185
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.